EyePoint Pharmaceuticals Gears Up for Investor Conferences
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company dedicated to developing and commercializing innovative treatments for patients with serious retinal diseases, has announced its participation in several important upcoming investor conferences.
Upcoming Conferences
The management team will be attending the following significant events:
Morgan Stanley Annual Global Healthcare Conference
This conference will include one-on-one meetings with investors, providing an opportunity for direct engagement with company representatives. It is scheduled for an upcoming Wednesday.
Baird Global Healthcare Conference
At this conference, EyePoint Pharmaceuticals will participate in a fireside chat, sharing insights about the company's progress and future strategies. This event is set for the coming Tuesday at 4:20 p.m. ET.
Cantor Global Healthcare Conference
During the fireside chat at this conference, EyePoint will delve deeper into its pipeline and product candidates. This event is planned for a Wednesday at 11:30 a.m. ET.
UBS Virtual Ophthalmology Day
This virtual event will also feature a fireside chat with EyePoint Pharmaceuticals, scheduled for a Wednesday at 2:30 p.m. ET.
Webcast Availability
A live webcast of the discussions, along with an archived replay, will be available in the Investors section of the company's official website.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals specializes in innovative treatments for serious retinal diseases. The company's pipeline is primarily supported by its proprietary bioerodible Durasert E™ technology, which allows for sustained drug delivery within the eye. Its leading product candidate, DURAVYU™ (formerly known as EYP-1901), marks a significant advancement in the treatment of VEGF-mediated retinal diseases. This investigational drug combines vorolanib, a selective tyrosine kinase inhibitor, with Durasert E™ technology to ensure continuous drug release.
Current Research and Development
DURAVYU is currently undergoing Phase 2 clinical trials aimed at addressing conditions such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), which are among the leading causes of vision loss in older adults in the United States. EyePoint anticipates starting pivotal Phase 3 trials for wet AMD in the near future.
Additional Pipeline Products
EyePoint’s pipeline also features EYP-2301, a promising TIE-2 agonist formulation designed to improve outcomes for patients with serious retinal conditions. The Durasert® technology has been successfully utilized in four FDA-approved products, demonstrating its efficacy and safety.
Licensing Agreements
Vorolanib, a crucial component of EyePoint's therapies, is exclusively licensed from Equinox Sciences, part of the Betta Pharmaceuticals group, for the treatment of localized ophthalmic diseases.
Contact Information for Investors and Media
If you are an investor and have inquiries, please contact:
Christina Tartaglia
Precision AQ
Direct: 212-698-8700
christina.tartaglia@precisionaq.com
For media inquiries, please reach out to:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
Frequently Asked Questions
What is EyePoint Pharmaceuticals known for?
EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing innovative therapeutics for serious retinal diseases.
What are the key upcoming events for EyePoint Pharmaceuticals?
EyePoint is set to participate in several investor conferences, including those hosted by Morgan Stanley, Baird, Cantor, and UBS.
What is the lead product candidate of EyePoint Pharmaceuticals?
The lead product candidate is DURAVYU™, an investigational sustained delivery treatment for VEGF-mediated retinal diseases.
What technologies does EyePoint Pharmaceuticals utilize?
The company employs its proprietary bioerodible Durasert E™ technology to ensure sustainable drug delivery within the eye.
Where can I find more information about EyePoint Pharmaceuticals?
Additional information is available on the company's official website and during their upcoming investor presentations.
